Opendata, web and dolomites

CXCR4THERAPY TERMINATED

IMPROVING HEMATOPOIETIC STEM CELL- BASED GENE THERAPY OUTCOME BY MODULATING CXCR4 EXPRESSION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CXCR4THERAPY project word cloud

Explore the words cloud of the CXCR4THERAPY project. It provides you a very rough idea of what is the project "CXCR4THERAPY" about.

fact    restricted    receptor    eliminate    transplantation    data    allogeneic    hemoglobin    hbb    correction    hscs    marrow    chemokine    thalassemias    treatment    clinical    endow    curative    homing    normally    abnormal    despite    broad    levels    compatible    defective    cell    disease    copy    regimen    mediated    globin    noteworthy    expression    followed    introduction    therapeutic    donors    regulating    amenable    compete    lv    potentially    capacity    thanks    intend    therapy    strategies    scd    synthesis    enhances    haploinsufficiency    competition    modulating    explored    option    vector    autologous    functional    gene    toxicity    milder    transiently    attaining    homed    reduce    bm    hurdle    patients    confer    innovative    endogenous    preclude    lentiviral    lvs    vivo    conditioning    inefficient    benefit    limited    alternative    advantage    mutations    stem    severely    cells    beta    burden    sickle    migration    transduced    diseases    hsc    strategy    competitive    corrected    proliferation    cxcr4    variant    bone    repopulating    hematopoietic    efficiencies    engraftment    caused   

Project "CXCR4THERAPY" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 173˙076 €
 EC max contribution 173˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 173˙076.00

Map

 Project objective

β-thalassemias and sickle cell disease (SCD) are caused by mutations in the β-globin gene (HBB) that result in the defective synthesis (β-thalassemias) or the production of an abnormal variant (SCD) of hemoglobin. Currently, the only curative option is allogeneic transplantation of hematopoietic stem cells (HSCs), but it is severely limited by conditioning toxicity and the restricted availability of compatible donors. Alternative strategies, based on lentiviral vector (LV)-mediated introduction of a functional copy of the HBB gene followed by autologous transplantation, are currently explored. Despite the fact that clinical data are promising, achieving a broad therapeutic benefit still remains a major hurdle because of inefficient gene correction and competition of the endogenous affected HSCs. In this proposal, I intend to confer an in vivo competitive advantage to transduced HSCs in terms of homing and engraftment efficiencies by modulating the expression levels of the chemokine receptor CXCR4 through two different approaches. On one hand, as increased CXCR4 levels enhance bone marrow (BM) homing, I will develop an innovative LV-based strategy to transiently deliver CXCR4 into HSCs to improve their migration to the BM. On the other hand, as CXCR4 haploinsufficiency enhances proliferation of homed HSCs, I will develop LVs down-regulating CXCR4 expression to endow corrected HSCs with an increased BM repopulating capacity. Thanks to these strategies, corrected HSCs will be able to out-compete non-corrected as well as endogenous affected HSCs, thus attaining therapeutic levels of engraftment even with a reduced number of corrected HSCs. In addition, this will contribute to use a milder conditioning regimen, normally required to eliminate endogenous affected HSCs, and thus reduce its toxicity, which preclude this treatment for patients with high disease burden. Noteworthy, this approach can potentially benefit many diseases amenable to HSC gene therapy.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CXCR4THERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CXCR4THERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

FOCUSIS (2020)

Focal volume Control Using Structured Illumination Sources

Read More  

MarshFlux (2020)

The effect of future global climate and land-use change on greenhouse gas fluxes and microbial processes in salt marshes

Read More